Innovent Biologics (1801) Collaboration summary

Opening remarks and agenda

• Announced a significant global strategic collaboration to accelerate next-generation IO and ADC cancer therapies, with presentations from key executives and Q&A sessions, including conference calls in Chinese and English on October 22, 2025.

• Agenda included updates on globalization strategy, partnership details, program overviews, and management presentations.

Objectives of the partnership

• Aim to co-develop and co-commercialize innovative oncology therapies globally, empowering patients with affordable, high-quality biopharmaceuticals.

• Accelerate global development and commercialization of late-stage and early-stage IO and ADC assets, targeting unmet medical needs worldwide.

• Partnership supports the goal of becoming a global premier biopharma by 2030, leveraging a solid domestic foundation and global operations.

Partner introductions and roles

• Takeda, a global biopharma leader with headquarters in Tokyo and a major hub in Cambridge, MA, operates in 80+ countries with $30.6B FY24 revenue and 50,000 employees, bringing deep scientific, regulatory, and commercial expertise, especially in oncology.

• Innovent contributes pioneering R&D in IO and ADC, with integrated global R&D and clinical operations and a robust pipeline.

• Key leaders from both companies, including Dr. PK Morrow (Takeda) and Dr. Michael Yu (Innovent), are actively involved.